US EditionPassage Bio Reports Progress in Gene Therapy for Frontotemporal Dementia
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Passage Bio Reports Progress in Gene Therapy for Frontotemporal Dementia
PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced encouraging updates from the ongoing Phase 1/2 upliFT-D clinical trial for PBFT02, a one-time gene therapy for frontotemporal dementia (FTD) caused by granulin (GRN) mutations. The data reflect robust biomarker improvements and durable effects, supporting the promise of PBFT02 as a groundbreaking treatment for this devastating neurodegenerative disease. PBFT02, using a gene replac…
An interdisciplinary team—leaded by Dr. Isabel Lastres-Becker, of the Instituto de Investigaciones Biomédicas “Sols-Morreale” and the Department of Biochemistry of the Autonomous University of Madrid (UAM)—has investigated the... La entrada Madrid researchers achieve neuroprotective effects in a model of frontotemporal dementia was first published in Gazetín Madrid.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
